EXONDYS 51

PeakRNA

eteplirsen

NDAINTRAVENOUSSOLUTIONPriority Review
Approved
Sep 2016
Lifecycle
Peak
Competitive Pressure
0/100

Mechanism of Action

51 of dystrophin pre-mRNA, resulting in exclusion of this exon during mRNA processing in patients with genetic mutations that are amenable to exon 51 skipping. Exon skipping is intended to allow for production of an internally truncated dystrophin protein, which was evaluated in Study 2 and Study 3…

Pharmacologic Class:

Antisense Oligonucleotide

Loss of Exclusivity

LOE Date
Mar 14, 2034
97 months away
Patent Expiry
Mar 14, 2034

Patent Records (5)

Patent #ExpiryTypeUse Code
RE48468
Oct 27, 2028
U-2097
RE47769
Feb 2, 2029
Product
10337003
Mar 14, 2034
U-1918
10364431
Mar 14, 2034
U-1918
9506058
Mar 14, 2034
U-1919